Company Overview of Sandoz Inc.
Sandoz Inc. develops, manufactures, markets, and distributes generic pharmaceutical products. Its therapeutic drug categories include anti-infectives, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agents, oncology therapies, respiratory therapies, alimentary tract and metabolism, blood and blood-forming organs, and antineoplastic and immunomodulating agents. The company provides oral solid generics to advanced application forms, such as transdermal patches and implants; and complex products, such as follow-on biologics (biosimilars), injectables, and inhalables. It sells its products to small and large retailers, wholesalers, hospitals, prescription b...
100 College Road West
Princeton, NJ 08540
Founded in 1946
Key Executives for Sandoz Inc.
President and Head of North America
Chief Financial Officer, Head of Finance - North America and Vice President
President of Oriel Therapeutics
Vice President of Legal, Ip & Compliance and General Counsel of North America
Vice President and Head of Biopharmaceuticals - North America
Compensation as of Fiscal Year 2014.
Sandoz Inc. Key Developments
Sandoz Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Reports Impairment Charges
Jan 27 15
Sandoz announced unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net sales were USD 2.5 billion against USD 2.41 billion a year ago. Operating income was USD 290 million against USD 276 million a year ago. Core operating income was USD 416 million against USD 373 million a year ago.
For the full year, the company reported net sales were USD 9.56 billion against USD 9.16 billion a year ago. Operating income was USD 1.09 billion against USD 1.03 billion a year ago. Core operating income was USD 1.57 billion against USD 1.54 billion a year ago. Operating income increased by 6%, benefiting from strong operating performance and unrepeated prior-year legal settlements.
The company reported total impairment charges of USD 18 million for the fourth quarter of 2014.
Helsinn Healthcare SA Reaches Settlement Agreement Regarding Patent Dispute on Aloxi® with Sandoz Inc
Jan 12 15
Helsinn Healthcare SA announced that it has entered into a settlement agreement with Sandoz Inc. to resolve their patent litigations relating to Helsinn Healthcare's Aloxi® (palonosetron HCl injection) in the US, where it is currently distributed by Helsinn Healthcare's marketing partner, Eisai Inc. As a result of the settlement, Sandoz Inc. will be permitted to market a generic version of Aloxi® in the United States on September 30, 2018 or earlier under certain circumstances. The terms of the settlement agreement are otherwise confidential.
Sandoz Launches Estradiol Transdermal System to Treat Menopausal Symptoms
Jan 1 15
Sandoz Inc. has launched estradiol transdermal system, an authorized generic version of Vivelle-Dot, which is marketed by Novartis Pharmaceuticals Corporation. Estradiol transdermal system is indicated for treatment of certain menopausal symptoms and for the prevention of postmenopausal osteoporosis.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|